The most significant recent advances in the application of monoclonal antibodies (mAbs) to
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …

Monoclonal antibody therapy has emerged as an important therapeutic modality for cancer.
Unconjugated antibodies show significant efficacy in the treatment of breast cancer, non …

Targeted therapies are the focus of much research in oncology. After the development of
imatinib for the treatment of chronic myeloid leukaemia, biological therapies that target …

Advances in immunoconjugate technology have revitalized the" magic bullet" concept of
immunotherapeutics for the treatment of cancer. The growing availability of" human" …

When delivered at a sufficient dose and dose rate to a neoplastic mass, radiation can kill
tumor cells. Because cancer frequently presents as a disseminated disease, it is imperative …

Monoclonal antibodies have emerged as a class of novel oncology therapeutics. The
selectivity and specificity, the unique pharmacokinetics, and the ability to engage and …

ABSTRACT Immunotherapy of cancer has been explored for over a century, but it is only in
the last decade that various antibody‐based products have been introduced into the …

Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked
covalently to an antibody or antibody fragment directed toward a specific cell surface target …

This review discusses the current limitations and future prospects of radiolabeled antibodies
in cancer imaging (radioimmunodetection, or RAID) and therapy (radioimmunotherapy, or …

Monoclonal antibodies have been developed to target specific proteins involved in the
development and progression of cancer. These reagents have the advantage of exquiste …